What To Know
- The ability to utilize multiple sites of service, with no incisions and a rapid recovery, is one of the most important recent treatment advances for women with symptomatic fibroids and their physicians, not only in Texas, but across the globe.
- John Thoppil is the first physician in the state of Texas to offer its Sonata® Treatment to women with symptomatic uterine fibroids as an office-based procedure at his River Place OB/GYN facility in Austin.
Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Dr. John Thoppil is the first physician in the state of Texas to offer its Sonata® Treatment to women with symptomatic uterine fibroids as an office-based procedure at his River Place OB/GYN facility in Austin.
“I am excited to offer this transcervical option for fibroid treatment in an office setting. Sonata is brilliant in concept; it reduces symptoms without any incisions at all,” said John Thoppil, MD, FACOG and President of TAOG. “We are honored to be the first medical group to offer Sonata in-office, in the state of Texas. In addition to the office, we will be offering the procedure in the traditional outpatient surgical center setting. The ability to utilize multiple sites of service, with no incisions and a rapid recovery, is one of the most important recent treatment advances for women with symptomatic fibroids and their physicians, not only in Texas, but across the globe.”
The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids. The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wider range of fibroid types, sizes, and locations than hysteroscopic myomectomy. Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained. (FDA cleared.)
“We are incredibly fortunate to have advocates like Dr. Thoppil, who are able to quickly utilize the advantages unique to the Sonata Transcervical Fibroid Ablation (TFA) Procedure,” said Chris Owens, President and CEO of Gynesonics. “The recent guidelines released by the American College of Obstetricians and Gynecologists (ACOG) recognized TFA as an important fibroid treatment that can be offered to women. Sonata is the only fibroid ablation system that does not require incisions or abdominal surgery. Sonata has been uniquely designed to help patients gain access to care through multiple sites of service, supporting rapid adoption around the globe.”
